keyword
MENU ▼
Read by QxMD icon Read
search

chronic lymphocytic leukaemia

keyword
https://www.readbyqxmd.com/read/29136691/-tumors-of-lymphoid-and-hematopoietic-tissue-of-spleen-a-clinicopathologic-analysis-of-53-cases
#1
D B Chen, D H Shen, H Zhang, Y Wang, Q J Song, S M Yang, X Z Fang
Objective: To study the clinicopathologic features, diagnosis and differential diagnosis of the tumors of lymphoidand hematopoietic tissue of the spleen(TLTS). Methods: Fifty-three cases of TLTS were selected from the pathologic files from Peking University People's Hospital from April 2002 to April 2017. According to WHO classification of tumors of hematopoietic and lymphoid tissues (2008) and its updated classification (2016), the cases were studied by microscopy, immunohistochemistry and in situ hybridization, combined with the bone marrow biopsy and clinical examination...
November 8, 2017: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/29127596/international-development-of-four-eortc-disease-specific-quality-of-life-questionnaires-for-patients-with-hodgkin-lymphoma-high-and-low-grade-non-hodgkin-lymphoma-and-chronic-lymphocytic-leukaemia
#2
Lonneke van de Poll-Franse, Simone Oerlemans, Anne Bredart, Charalampia Kyriakou, Monika Sztankay, Stephan Pallua, Laurien Daniëls, Carien L Creutzberg, Kim Cocks, Sandra Malak, Giovanni Caocci, Stefano Molica, Weichu Chie, Fabio Efficace
PURPOSE: This paper describes the international, cross-cultural development of four disease-specific EORTC QoL questionnaires, to supplement the EORTC QLQ-C30, for patients with Hodgkin lymphoma (HL), high- or low-grade non-Hodgkin lymphoma (HG/LG-NHL), and CLL. METHODS: Questionnaire development was conducted according to guidelines from the EORTC Quality of Life Group. Phase I comprised generation of QoL issues relevant to patients. Phase II included operationalization and assessment of item relevance...
November 10, 2017: Quality of Life Research
https://www.readbyqxmd.com/read/29122897/polymyalgia-rheumatica-development-in-a-patient-under-pi3k-inhibitor-therapy-for-chronic-lymphocytic-leukaemia
#3
Sanah Sajawal, Sarah L Mackie, Peter Hillmen, Dennis McGonagle
We report a patient with chronic lymphocytic leukaemia (CLL) who was treated with idelalisib, a PI3Kδ inhibitor with rituximab. After 20 weeks of treatment, the patient developed classical signs and symptoms of polymyalgia rheumatica (PMR) in association with an elevated C reactive protein of 74 mg/L. After 2 weeks of prednisolone 15 mg daily symptoms had resolved and acute phase markers normalised. To our knowledge, this is the first report of PMR developing as a complication of PI3Kδ inhibitor treatment of CLL...
November 8, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/29099483/the-bcl-2-arbiters-of-apoptosis-and-their-growing-role-as-cancer-targets
#4
REVIEW
Jerry M Adams, Suzanne Cory
Impaired apoptosis plays a central role in cancer development and limits the efficacy of conventional cytotoxic therapies. Deepening understanding of how opposing factions of the BCL-2 protein family switch on apoptosis and of their structures has driven development of a new class of cancer drugs that targets various pro-survival members by mimicking their natural inhibitors, the BH3-only proteins. These 'BH3 mimetic' drugs seem destined to become powerful new weapons in the arsenal against cancer. Successful clinical trials of venetoclax/ABT-199, a specific inhibitor of BCL-2, have led to its approval for a refractory form of chronic lymphocytic leukaemia and to scores of on-going trials for other malignancies...
November 3, 2017: Cell Death and Differentiation
https://www.readbyqxmd.com/read/29093626/faecal-microbiota-transplantation-in-patients-with-clostridium-difficile-and-significant-comorbidities-as-well-as-in-patients-with-new-indications-a-case-series
#5
Perttu Lahtinen, Eero Mattila, Veli-Jukka Anttila, Jyrki Tillonen, Matti Teittinen, Pasi Nevalainen, Seppo Salminen, Reetta Satokari, Perttu Arkkila
Fecal microbiota transplantation (FMT) is effective in recurrent Clostridium difficile infection (rCDI). Knowledge of the safety and efficacy of FMT treatment in immune deficient patients is scarce. FMT has been suggested as a potential method for an increasing number of new indications besides rCDI. Among our FMT-treated rCDI patients, we reviewed those with major comorbidities: two human immunodeficiency virus patients, six haemodialysis patients, two kidney transplant patients, two liver transplant patients and a patient with chronic lymphatic leukaemia...
October 21, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29074954/functional-activation-of-osteoclast-commitment-in-chronic-lymphocytic-leukaemia-a-possible-role-for-rank-rankl-pathway
#6
Cecilia Marini, Silvia Bruno, Francesco Fiz, Cristina Campi, Roberta Piva, Giovanna Cutrona, Serena Matis, Alberto Nieri, Maurizio Miglino, Adalberto Ibatici, Anna Maria Orengo, Anna Maria Massone, Carlo Emanuele Neumaier, Daniela de Totero, Paolo Giannoni, Matteo Bauckneht, Michele Pennone, Claudya Tenca, Elena Gugiatti, Alessandro Bellini, Anna Borra, Elisabetta Tedone, Hülya Efetürk, Francesca Rosa, Laura Emionite, Michele Cilli, Davide Bagnara, Valerio Brucato, Paolo Bruzzi, Michele Piana, Franco Fais, Gianmario Sambuceti
Skeletal erosion has been found to represent an independent prognostic indicator in patients with advanced stages of chronic lymphocytic leukaemia (CLL). Whether this phenomenon also occurs in early CLL phases and its underlying mechanisms have yet to be fully elucidated. In this study, we prospectively enrolled 36 consecutive treatment-naïve patients to analyse skeletal structure and bone marrow distribution using a computational approach to PET/CT images. This evaluation was combined with the analysis of RANK/RANKL loop activation in the leukemic clone, given recent reports on its role in CLL progression...
October 26, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29071273/chronic-lymphocytic-leukaemia-small-cell-lymphocytic-lymphoma-of-the-lacrimal-sac-a-case-series
#7
Yamini Krishna, Luciane D Irion, Sozan Karim, Aruna Dharmsena, Austin McCormick, Sarah E Coupland
BACKGROUND: Lymphomas of the lacrimal sac are rare, accounting for less than 10% of lacrimal sac malignant tumours. They may present with symptoms typical of secondary acquired nasolacrimal duct obstruction and are thus often misdiagnosed. METHODS: Case series and literature review. RESULTS: Herein we describe 3 cases of chronic lymphocytic leukaemia (CLL)/small-cell lymphocytic lymphoma (SLL) of the lacrimal sac with immunohistochemical and in 1 case molecular confirmation...
September 2017: Ocular Oncology and Pathology
https://www.readbyqxmd.com/read/29044464/prognostic-value-of-the-cancer-oncogene-kelch-like-6-in-gastric-cancer
#8
J Deng, J Guo, G Ma, H Zhang, D Sun, Y Hou, X Xie, X Guo, Y Nie, H Liang
BACKGROUND: Kelch-like 6 (KLHL6) is a cancer oncogene previously associated with specific human cancers, such as chronic lymphocytic leukaemia. Here, the mechanisms of KLHL6 function were explored in gastric cancer (GC) cells, in an in vivo experimental tumour model, and the prognostic value of KLHL6 analysis in GC tissue evaluated in a cohort of patients with GC. METHODS: Associations between clinicopathological and survival data and KLHL6 expression in GC tissues were analysed...
October 17, 2017: British Journal of Surgery
https://www.readbyqxmd.com/read/29034706/chronic-lymphocytic-leukaemia-and-secondary-skin-malignancies
#9
Geraldine Kyle
Chronic lymphocytic leukaemia (CLL) is a non-Hodgkin lymphoma commonly occurring in older adults. Many people with CLL can go for years without requiring treatment. However, they have an increased risk of secondary cancers, specifically melanoma and non-melanoma skin cancers. Furthermore, these secondary cancers are frequently more aggressive in this cohort of patients. Health professionals working in haematology, dermatology and general practice have an opportunity to educate patients about risk factors and measures to aid prevention...
October 12, 2017: British Journal of Nursing: BJN
https://www.readbyqxmd.com/read/29025288/-state-of-the-art-molecular-diagnostics-and-therapy-of-chronic-lymphocytic-leukaemia-in-the-era-of-new-targeted-therapies
#10
Tímea Gurbity Pálfi, Viktória Fésüs, Csaba Bödör, Zita Borbényi
Chronic lymphoid leukaemia (CLL) has a heterogeneous clinical course depending on many clinical and molecular prognostic markers, which play an important role in the selection of the best treatment option. So far, TP53 disruption is the key prognostic and predictive factor assisting treatment decisions, especially in the era of novel therapies. Asymptomatic patients in early stages of the disease will still benefit from watchful waiting. In the frontline setting, chemoimmunotherapy is still the standard care in the majority of standard risk CLL patients...
October 2017: Orvosi Hetilap
https://www.readbyqxmd.com/read/29024518/cd5-b-lymphoproliferative-disorder-with-subsequent-development-of-plasma-cell-leukaemia-diagnostic-and-aetiologic-reasoning
#11
Evdoxia Gounari, Georgia Kaiafa, Triantafyllia Koletsa, Vasiliki Tsavdaridou, Ioannis Kostopoulos, Lilian Toptsi, Lemonia Skoura
BACKGROUND: Plasma cell myeloma (PCM) has been sporadically reported to occur simultaneously or subsequently to mature B lymphoproliferative disorders (LPDs), predominantly chronic lymphocytic leukaemia (CLL). METHODS: We describe the clinical and laboratory findings of a 69-year-old male patient who developed plasma cell leukaemia (PCL) 8 years after an initial diagnosis of a low stage CD5+ B LPD and 3 years after treatment for LPD. RESULTS: The transition from a clinically indolent B LPD to an aggressive PCM was documented by bone marrow (BM) biopsy, while flow cytometric (FC) immunophenotyping conferred additional information by disclosing the co-existence of both disorders in BM and the presence of abnormal monotypic PCs in peripheral blood above PCL levels...
October 10, 2017: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/28990156/microtubule-associated-protein-1a-1b-light-chain-3-lc3-decorates-intracytoplasmic-inclusions-in-a-patient-with-chronic-lymphocytic-leukaemia
#12
Claudio Bussi, Pablo Iribarren, Cecilia M Rodriguez
No abstract text is available yet for this article.
October 8, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28978601/isolated-cerebral-mucormycosis-caused-by-rhizomucor-pusillus
#13
Saira Farid, Omar AbuSaleh, Rachael Liesman, Muhammad Rizwan Sohail
A 61-year-old man with relapsing chronic lymphocytic leukaemia, status post allogeneic stem cell transplant and multiple chemotherapy regimens presented to the emergency room after suffering a grand mal seizure. His evaluation revealed a 1.5-2 cm ring-enhancing left temporal lobe brain lesion on the CT scan. This brain lesion was resected and the histopathology revealed an invasive fungal organism resembling mucormycosis. Amplification and sequencing of the 28S ribosomal RNA gene identified the organism as Rhizomucor pusillus The patient was treated with liposomal amphotericin B 5 mg/kg every 24 hours for 4 weeks, and then was transitioned to oral posaconazole...
October 4, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28972968/30-years-follow-up-and-increased-risks-of-breast-cancer-and-leukaemia-after-long-term-low-dose-rate-radiation-exposure
#14
Wan-Hua Hsieh, I-Feng Lin, Jung-Chun Ho, Peter Wushou Chang
BACKGROUND: The current study followed-up site-specific cancer risks in an unique cohort with 30 years' follow-up after long-term low-dose-rate radiation exposure in Taiwan. METHODS: 6242 Taiwanese people received extra exposure in residential and school buildings constructed with Co-60-contaminated steel from 1982 until informed and relocated in early 1990s. The additional doses received have been estimated. During 1983-2012, 300 cancer cases were identified through the national cancer registry in Taiwan, 247 cases with minimum latent periods from initial exposure...
October 3, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28972490/phagocytosis-and-expression-of-fcg-receptors-and-cd180-on-monocytes-in-chronic-lymphocytic-leukemia
#15
T Tsertsvadze, N Mitskevich, A Bilanishvili, D Girdaladze, N Porakishvili
Chronic lymphocytic leukaemia (CLL) is a lymphoproliferative disease characterised by accumulation of monoclonal CD19+CD5+CD23+ lymphocytes in the peripheral blood and bone marrow. CLL is the most common type of the adult leukemia in the Western world. The disease is incurable, albeit there are new molecular and immunotherapy methods currently available in conjunction with chemotherapy, leading to the "precision therapy". The majority of immunotherapeutic approaches are based on the ability of therapeutic antibodies (Rituximab, Alemtuzumab) to mobilize anti-tumour potential of the Natural Killer cells and macrophages/monocytes through their Fcg-receptors (FcγR)...
September 2017: Georgian Medical News
https://www.readbyqxmd.com/read/28970470/nfat2-is-a-critical-regulator-of-the-anergic-phenotype-in-chronic-lymphocytic-leukaemia
#16
Melanie Märklin, Jonas S Heitmann, Alexander R Fuchs, Felicia M Truckenmüller, Michael Gutknecht, Stefanie Bugl, Sebastian J Saur, Juliane Lazarus, Ursula Kohlhofer, Leticia Quintanilla-Martinez, Hans-Georg Rammensee, Helmut R Salih, Hans-Georg Kopp, Michael Haap, Andreas Kirschniak, Lothar Kanz, Anjana Rao, Stefan Wirths, Martin R Müller
Chronic lymphocytic leukaemia (CLL) is a clonal disorder of mature B cells. Most patients are characterised by an indolent disease course and an anergic phenotype of their leukaemia cells, which refers to a state of unresponsiveness to B cell receptor stimulation. Up to 10% of CLL patients transform from an indolent subtype to an aggressive form of B cell lymphoma over time (Richter´s syndrome) and show a significantly worse treatment outcome. Here we show that B cell-specific ablation of Nfat2 leads to the loss of the anergic phenotype culminating in a significantly compromised life expectancy and transformation to aggressive disease...
October 2, 2017: Nature Communications
https://www.readbyqxmd.com/read/28958469/lenalidomide-maintenance-therapy-in-previously-treated-chronic-lymphocytic-leukaemia-continuum-a-randomised-double-blind-placebo-controlled-phase-3-trial
#17
Asher A Chanan-Khan, Andrey Zaritskey, Miklos Egyed, Samuel Vokurka, Sergey Semochkin, Anna Schuh, Jeannine Kassis, David Simpson, Jennie Zhang, Brendan Purse, Robin Foà
BACKGROUND: The efficacy and safety of lenalidomide as maintenance therapy after chemotherapy-based second-line therapy in patients with chronic lymphocytic leukaemia is unknown. Although kinase inhibitors can improve outcomes for some patients with relapsed and refractory disease, not all patients have access to these novel drugs. In this study, we aimed to assess the efficacy and safety of lenalidomide as maintenance therapy in patients with previously treated chronic lymphocytic leukaemia...
September 25, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28921160/gp2013-a-rituximab-biosimilar
#18
Hannah A Blair
GP2013 is the second biosimilar of the reference monoclonal anti-CD20 antibody rituximab to be approved in the EU. It is approved for use in all indications for which reference rituximab is approved, including follicular lymphoma (FL), diffuse large B-cell non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis (RA), granulomatosis with polyangiitis and microscopic polyangiitis. GP2013 has similar physicochemical and pharmacodynamic properties to those of reference rituximab, and the pharmacokinetic biosimilarity of the agents has been shown in patients with RA...
September 18, 2017: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/28916317/presence-of-human-herpesvirus-8-hhv-8-dna-sequences-in-patients-with-lymphoproliferative-diseases-and-chronic-blood-disorders
#19
Hossein Keyvani, Mohammad Hadi Karbalaie Niya, Maryam Esghaei, Farah Bokharaei-Salim, Seyed Hamid Reza Monavari
OBJECTIVE: Human herpesvirus 8 (HHV-8) is the causative agent of Kaposi's sarcoma (KS), but it has also been associated with different hematologic malignancies, including plasmablastic lymphoma, Multicentric Castleman's disease (MCD), primary effusion lymphoma (PEL) and various atypical lymphoproliferative disorders. Patients with underlying lymphoproliferative diseases and chronic blood disorders who become infected with this virus are at risk for human malignancies. This small study reported the frequency of human herpesvirus 8 in 81 Iranian patients with lymphoproliferative disorders for estimation of possible factors affecting malignancy...
October 2017: Microbial Pathogenesis
https://www.readbyqxmd.com/read/28916312/lenalidomide-maintenance-in-high-risk-chronic-lymphocytic-leukaemia-practice-changing-study-or-hypothesis-generating-approach
#20
Davide Rossi, Adalgisa Condoluci
No abstract text is available yet for this article.
September 12, 2017: Lancet Haematology
keyword
keyword
68560
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"